Ribitol
Sponsors
ML Bio Solutions Inc.
Conditions
Limb Girdle Muscular Dystrophy (LGMD) Type 2ILimb Girdle Muscular Dystrophy 2I/R9
Phase 3
A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of BBP-418 (ribitol) in Patients with Limb Girdle Muscular Dystrophy 2I (LGMD2I)
Active, not recruitingCTIS2023-503379-33-01
Start: 2024-02-12Target: 35Updated: 2025-12-11
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)
Not yet recruitingCTIS2025-524371-23-00
Target: 22Updated: 2026-06-16